TD Asset Management’s Myriad Genetics MYGN Stock Holding History

TD Asset Management’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-6,650	Closed	-$226K	–	1395
2014 Q4	$226K	Buy	+6,650	New	+$236K	﹤0.01%	1303
2013 Q3	–	Sell	-9,321	Closed	-$250K	–	1267
2013 Q2	$250K	Buy	+9,321	New	+$270K	﹤0.01%	1082

Other funds holding MYGN

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BTS

BB&T Securities Richmond, Virginia $10.9B AUM 5.31% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

TD Asset Management's MYGN Position: Q1 2015 in Review

TD Asset Management sold out of Myriad Genetics (MYGN) in Q1 2015, closing a stake of 6,650 shares — an estimated $226K sold.

TD Asset Management first reported a position in MYGN in Q2 2013 and held it in 2 quarters. The position peaked at $250K in Q2 2013. 251 funds tracked by Wall St. Rank hold MYGN as of Q1 2015.

TD Asset Management reported no remaining Myriad Genetics position as of Q1 2015 after selling out during the quarter.
TD Asset Management sold 6,650 Myriad Genetics shares in Q1 2015, an estimated $226K.
TD Asset Management first reported a position in Myriad Genetics in Q2 2013 and held it in 2 quarters.
TD Asset Management's Myriad Genetics position peaked at $250K in Q2 2013.
251 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2015.

Based on TD Asset Management's 13F filing for Q1 2015, filed 28 Apr 2015.